English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Until recently, arterial stenosis and occlusion due to buildup of atherosclerotic plaque were recognized as the primary causes of coronary heart disease (CHD). Currently, CHD is viewed as a lifelong process of endothelial inflammation, thrombosis, and plaque instability and rupture. Lifestyle modification is an important first step in prevention of CHD, but even those patients who are the most committed to following a healthy diet and lifestyle frequently require the addition of drug therapy to further reduce risk. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduce risk by lowering low-density lipoprotein cholesterol levels, as well as by stabilizing plaques, restoring endothelial function, and counteracting oxidative and inflammatory processes. Angiotensin-converting enzyme inhibitors also have antiatherogenic properties. Early, aggressive lipid intervention is the key to primary and secondary prevention of CHD.

Recent discoveries in assessment of coronary heart disease: impact of vascular mechanisms on development of atherosclerosis